Aytu BioPharma Inc. (NASDAQ:AYTU) Short Interest Update

Aytu BioPharma Inc. (NASDAQ:AYTU) was the recipient of a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling 453,509 shares, a decrease of 17.3% from the January 29th total of 548,197 shares. Based on an average daily trading volume, of 78,178 shares, the days-to-cover ratio is currently 5.8 days. Currently, 4.4% of the company’s shares are short sold. Currently, 4.4% of the company’s shares are short sold. Based on an average daily trading volume, of 78,178 shares, the days-to-cover ratio is currently 5.8 days.

Aytu BioPharma Price Performance

NASDAQ AYTU opened at $2.61 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.03 and a current ratio of 1.16. The stock has a market cap of $28.01 million, a price-to-earnings ratio of -0.68 and a beta of 0.35. The business has a 50 day simple moving average of $2.53 and a 200 day simple moving average of $2.33. Aytu BioPharma has a 52-week low of $0.95 and a 52-week high of $3.07.

Aytu BioPharma (NASDAQ:AYTU) last released its quarterly earnings results on Tuesday, February 3rd. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.79). Aytu BioPharma had a negative net margin of 39.02% and a negative return on equity of 28.22%. The company had revenue of $15.17 million during the quarter, compared to analyst estimates of $12.17 million.

Institutional Trading of Aytu BioPharma

Hedge funds and other institutional investors have recently modified their holdings of the company. Daytona Street Capital LLC acquired a new position in shares of Aytu BioPharma during the fourth quarter worth about $26,000. Rothschild Wealth LLC bought a new stake in Aytu BioPharma in the 4th quarter valued at approximately $52,000. Dimensional Fund Advisors LP acquired a new position in Aytu BioPharma during the 3rd quarter worth approximately $58,000. Bellevue Asset Management LLC bought a new position in shares of Aytu BioPharma during the 4th quarter worth approximately $65,000. Finally, XTX Topco Ltd acquired a new stake in shares of Aytu BioPharma in the fourth quarter valued at approximately $67,000. Institutional investors and hedge funds own 33.49% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Zacks Research upgraded Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research report on Monday. Wall Street Zen raised shares of Aytu BioPharma to a “hold” rating in a research note on Saturday, February 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Friday, January 9th. Finally, Ascendiant Capital Markets lifted their price target on shares of Aytu BioPharma from $12.50 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $9.33.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.